IL326147A - Methods for treating type 1 diabetes - Google Patents

Methods for treating type 1 diabetes

Info

Publication number
IL326147A
IL326147A IL326147A IL32614726A IL326147A IL 326147 A IL326147 A IL 326147A IL 326147 A IL326147 A IL 326147A IL 32614726 A IL32614726 A IL 32614726A IL 326147 A IL326147 A IL 326147A
Authority
IL
Israel
Prior art keywords
diabetes
methods
treating type
treating
type
Prior art date
Application number
IL326147A
Other languages
Hebrew (he)
Original Assignee
Provention Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc filed Critical Provention Bio Inc
Publication of IL326147A publication Critical patent/IL326147A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326147A 2023-07-27 2024-07-29 Methods for treating type 1 diabetes IL326147A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363515949P 2023-07-27 2023-07-27
US202363590883P 2023-10-17 2023-10-17
PCT/US2024/040020 WO2025024848A1 (en) 2023-07-27 2024-07-29 Methods for treating type 1 diabetes

Publications (1)

Publication Number Publication Date
IL326147A true IL326147A (en) 2026-03-01

Family

ID=92457137

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326147A IL326147A (en) 2023-07-27 2024-07-29 Methods for treating type 1 diabetes

Country Status (6)

Country Link
KR (1) KR20260046157A (en)
CN (1) CN121568962A (en)
AU (1) AU2024299422A1 (en)
IL (1) IL326147A (en)
TW (1) TW202521153A (en)
WO (1) WO2025024848A1 (en)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
ATE252894T1 (en) 1995-01-05 2003-11-15 Univ Michigan SURFACE-MODIFIED NANOPARTICLES AND METHODS FOR THEIR PRODUCTION AND USE
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
AU2006267090B2 (en) 2005-07-11 2013-03-07 Provention Bio, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MX2008015771A (en) 2006-06-14 2009-01-27 Macrogenics Inc Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity.
WO2022251253A1 (en) * 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4401773A4 (en) * 2021-09-13 2025-07-30 Provention Bio Inc Methods and compositions containing anti-CD3 antibodies and DYRK1A inhibitors for the treatment of diabetes
IL314694A (en) * 2022-05-24 2024-10-01 Provention Bio Inc Methods and compositions for preventing or delaying type 1 diabetes
TW202448505A (en) * 2023-03-01 2024-12-16 美商普泛森生技公司 Methods and compositions for treating type 1 diabetes
TW202506177A (en) * 2023-03-30 2025-02-16 美商普泛森生技公司 Methods for reducing exogenous insulin use

Also Published As

Publication number Publication date
WO2025024848A1 (en) 2025-01-30
AU2024299422A1 (en) 2026-03-12
TW202521153A (en) 2025-06-01
CN121568962A (en) 2026-02-24
KR20260046157A (en) 2026-04-06

Similar Documents

Publication Publication Date Title
IL288061A (en) Compounds and methods for treating covid-19
IL308628A (en) Methods for treating type 1 diabetes
IL327282A (en) New treatments for pain
EP4493175A4 (en) MIRDAMETINIB TREATMENT
DK4103178T3 (en) METHODS FOR TREATING FABRYS DISEASE
FI3952858T3 (en) METHOD FOR TREATING TUMORS
LT4034122T (en) TREATMENT METHODS FOR HYPERPHENYLALANEMIA
IL287130A (en) Methods for treating itching
EP4487349A4 (en) MACHINE LEARNING FOR PREDICTING BOLT TREATMENT
EP4521762A4 (en) PHOTOGRAPHY PROCESS
JP1735468S (en) sunglasses
EP4481051A4 (en) MODIFIED D-ALLULOSE-3-EPIMERASE
IL314050A (en) Combined treatment method for hepatocellular carcinoma
EP3773546A4 (en) METHOD FOR TREATING POSTPRANDIAL HYPOGLYCAEMIA
JP1750745S (en) sunglasses
IL311579A (en) Predictive methods for type 1 diabetes treatments
IL289824A (en) Methods for treating multiple sclerosis
EP4592765A4 (en) PROCESS CARTROTTUDE
IL316776A (en) Methods for treating pompe disease
IL313079A (en) Treatment methods using LOU064
EP4359114A4 (en) ENRICHEMENT PROCESS
EP4021446A4 (en) USEFUL COMPOUNDS FOR TREATING PAIN
EP4084767A4 (en) COMPOSITION FOR LIGHTENING OR BLEACHING KERATIN SUBSTANCES
EP4745676A1 (en) PROCESS CARTROTTUDE
EP4743549A1 (en) DESULFULATION PROCESS